{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:16:41Z","timestamp":1791346601878,"version":"4.3.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaip.2021.03.034","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T20:10:54Z","timestamp":1617394254000},"page":"2186-2194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age"],"prefix":"10.1016","volume":"9","author":[{"given":"Hilary J.","family":"Longhurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Godse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Ensina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.03.034_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/092986710790416326","article-title":"Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions","volume":"17","author":"Corsonello","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaip.2021.03.034_bib3","first-page":"214","article-title":"Epidemiology of urticaria in Spain","volume":"14","author":"Gaig","year":"2004","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3904\/kjim.2014.29.6.800","article-title":"Clinical features of elderly chronic urticaria","volume":"29","author":"Ban","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/ijd.12109","article-title":"Clinical and laboratory features of chronic idiopathic urticaria in the elderly","volume":"52","author":"Magen","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib7","first-page":"201","article-title":"Clinical features of chronic urticaria in aging population","volume":"34","author":"Chuamanochan","year":"2016","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1684\/ejd.2019.3674","article-title":"Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response","volume":"29","author":"Curto-Barredo","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/1346-8138.14075","article-title":"Epidemiology and comorbidities of patients with chronic urticaria in Korea: a nationwide population-based study","volume":"45","author":"Kim","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","article-title":"Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis","volume":"81","author":"Wertenteil","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib11","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.jaip.2020.03.030","article-title":"Urticaria and angioedema across the ages","volume":"8","author":"Saini","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia in chronic spontaneous urticaria is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib13","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria (aiCSU): results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib15","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaip.2018.05.006","article-title":"Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases","volume":"6","author":"Davis","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jdv.15984","article-title":"Neutrophilic urticarial dermatosis: an entity bridging monogenic and polygenic autoinflammatory disorders, and beyond","volume":"34","author":"Gusdorf","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.03.034_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ced.12828","article-title":"Clinical characterization and long-term follow-up of Schnitzler syndrome","volume":"41","author":"Gameiro","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/ejd.2016.2905","article-title":"Treatment of chronic spontaneous urticaria with an inadequate response to H 1-antihistamines: an expert opinion","volume":"27","author":"Vestergaard","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2500\/aap.2011.32.3483","article-title":"Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria","volume":"32","author":"Magen","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.03.034_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-019-0274-7","article-title":"High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema","volume":"9","author":"Hofman","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2018.01.023","article-title":"Urticaria: a comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes","volume":"79","author":"Antia","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","article-title":"Risk of first-generation H1-antihistamines: a GA2LEN position paper","volume":"65","author":"Church","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0023931","article-title":"H1-antihistamine up-dosing in chronic spontaneous urticaria: patients\u2019 perspective of effectiveness and side effects\u2014a retrospective survey study","volume":"6","author":"Weller","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.03.034_bib25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/cea.13500","article-title":"Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria","volume":"49","author":"Cataldi","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0019-5154.110832","article-title":"Pharmacology of antihistamines","volume":"58","author":"Church","year":"2013","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.14075","article-title":"Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic\/spontaneous urticaria: analyses according to the presence or absence of angioedema","volume":"31","author":"Maurer","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2021.03.034_bib28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/all.13339","article-title":"Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data","volume":"73","author":"Staubach","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13601-016-0120-0","article-title":"Improvement of sleep in patients with chronic idiopathic\/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies","volume":"6","author":"Gim\u00e9nez-Arnau","year":"2016","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria. A meta-analysis of \u201creal-world\u201d evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.16476","article-title":"Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria","volume":"179","author":"Kanters","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/ced.13173","article-title":"Long-term management of chronic spontaneous urticaria with omalizumab","volume":"42","author":"Pinto Gouveia","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib35","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2147\/DDDT.S214307","article-title":"Omalizumab for chronic spontaneous urticaria in \u201ccomplex\u201d patients: data from real-life clinical practice","volume":"13","author":"Vollono","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaip.2021.03.034_bib36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2017.12.007","article-title":"Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience","volume":"120","author":"Nettis","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjd.17005","article-title":"IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria","volume":"180","author":"Santiago","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.034_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-015-0088-7","article-title":"Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care","volume":"11","author":"Savic","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4168\/aair.2019.11.5.736","article-title":"Factors predicting the response to cyclosporin treatment in patients with chronic spontaneous urticaria\u202f: a systematic review","volume":"11","author":"Kulthanan","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2021.03.034_bib40","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Medicine"},{"key":"10.1016\/j.jaip.2021.03.034_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13601-019-0272-9","article-title":"Elderly versus younger patients with hereditary angioedema type I\/II: patient characteristics and safety analysis from the Icatibant Outcome Survey","volume":"9","author":"Bygum","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40266-016-0403-0","article-title":"Use of a C1 inhibitor concentrate in adults \u226565 years of age with hereditary angioedema: findings from the International Berinert\u00ae (C1-INH)","volume":"33","author":"Bygum","year":"2016","journal-title":"Registry. Drug Aging"},{"key":"10.1016\/j.jaip.2021.03.034_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","article-title":"Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema","volume":"125","author":"Bernstein","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib47","first-page":"320","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"2018","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.03.034_bib48","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.13908","article-title":"High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency","volume":"172","author":"Castelli","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2021.03.034_bib49","doi-asserted-by":"crossref","first-page":"e4363","DOI":"10.1097\/MD.0000000000004363","article-title":"A\u00a0nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients","volume":"95","author":"Gobert","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2021.03.034_bib50","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaip.2016.12.032","article-title":"Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency","volume":"5","author":"Zanichelli","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-019-1043-3","article-title":"Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate","volume":"14","author":"Bork","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2021.03.034_bib52","first-page":"A7184","article-title":"Recurrent isolated angioedema as a result of acquired C1 inhibitor deficiency [in Dutch]","volume":"158","author":"Bosma","year":"2014","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.jaip.2021.03.034_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13223-018-0274-5","article-title":"Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen","volume":"14","author":"Leru","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0091-6749(86)80111-7","article-title":"The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiency","volume":"77","author":"Melamed","year":"1986","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12032-018-1183-7","article-title":"Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization","volume":"35","author":"Sbattella","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.jaip.2021.03.034_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000467853","article-title":"Acquired C1 inhibitor deficiency with angioedema symptoms in a patient infected with Echinococcus granulosus","volume":"2","author":"Cicardi","year":"1985","journal-title":"Complement"},{"key":"10.1016\/j.jaip.2021.03.034_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2015-0195","article-title":"The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity","volume":"54","author":"Wu","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cei.12910","article-title":"Comparing acquired angioedema with hereditary angioedema (types I\/II): findings from the Icatibant Outcome Survey","volume":"188","author":"Longhurst","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib59","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","article-title":"A\u00a0focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema","volume":"131","author":"Zuraw","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.iac.2017.03.002","article-title":"Acquired C1 inhibitor deficiency","volume":"37","author":"Iris","year":"2017","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.jaip.2021.03.034_bib61","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.revmed.2020.06.010","article-title":"Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment [in French]","volume":"41","author":"Gobert","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jaip.2021.03.034_bib62","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/all.13103","article-title":"Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice","volume":"72","author":"Zanichelli","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib64","first-page":"523","article-title":"Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy","volume":"37","author":"Hauptmann","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/all.13686","article-title":"Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency","volume":"74","author":"Levi","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.anai.2013.12.024","article-title":"Acquired C1 inhibitor deficiency: should we monitor for associated antibody deficiency?","volume":"112","author":"Tohani","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib67","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12016-016-8575-2","article-title":"The humanistic, societal, and pharmaco-economic burden of angioedema","volume":"51","author":"Longhurst","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/157488612800492744","article-title":"The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials","volume":"7","author":"Ross","year":"2012","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jaip.2021.03.034_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11239-019-02034-1","article-title":"The efficacy and safety of tranexamic acid in the treatment of intertrochanteric fracture: an updated meta-analysis of 11 randomized controlled trials","volume":"50","author":"Yu","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jaip.2021.03.034_bib70","first-page":"CD000249","article-title":"Antifibrinolytics for heavy menstrual bleeding","author":"Lethaby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2021.03.034_bib71","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib72","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.3399\/bjgp12X659295","article-title":"Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?","volume":"62","author":"Calder\u00f3n-Larra\u00f1aga","year":"2012","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jaip.2021.03.034_bib73","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","author":"Mahmoudpour","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2021.03.034_bib74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/ACI.0b013e328362b835","article-title":"Angioedema induced by angiotensin-converting enzyme inhibitors","volume":"13","author":"Campo","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.anai.2014.06.019","article-title":"Multinational experience with hypersensitivity drug reactions in Latin America","volume":"113","author":"Jares","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib76","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1524-6175.2006.05689.x","article-title":"Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"8","author":"Piller","year":"2006","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.jaip.2021.03.034_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10875-015-0228-3","article-title":"Angioedema triggered by medication blocking the renin\/angiotensin system: retrospective study using the French National Pharmacovigilance Database","volume":"36","author":"Faisant","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib78","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/fcp.12313","article-title":"The impact of age and sex on the reporting of cough and angioedema with renin\u2013angiotensin system inhibitors: a case\/noncase study in VigiBase","volume":"31","author":"Alharbi","year":"2017","journal-title":"Fundam Clin Pharm"},{"key":"10.1016\/j.jaip.2021.03.034_bib79","doi-asserted-by":"crossref","first-page":"106081","DOI":"10.1016\/j.intimp.2019.106081","article-title":"ACE inhibitor-mediated angioedema","volume":"78","author":"Montinaro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2021.03.034_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2500\/ajra.2014.28.3989","article-title":"Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors","volume":"28","author":"Stauber","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-016-8585-0","article-title":"Efficacy of treatment of non-hereditary angioedema","volume":"54","author":"van den Elzen","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib82","first-page":"455","article-title":"Drug-induced angioedema: experience of Italian emergency departments","volume":"9","author":"Bertazzoni","year":"2014","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2332\/allergolint.12-RAI-0493","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2021.03.034_bib84","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/lary.26336","article-title":"The burden of angioedema on United States emergency departments: 2006-2010","volume":"127","author":"Smith","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2021.03.034_bib85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)\u2014classification, diagnosis and management: review of the EAACI\/ENDA# and GA2LEN\/HANNA\u2217","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib86","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/ACI.0000000000000292","article-title":"Angioedema associated with nonsteroidal anti-inflammatory drugs","volume":"16","author":"Giavina-Bianchi","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cea.12013","article-title":"Value of the clinical history in the diagnosis of urticaria\/angioedema induced by NSAIDs with cross-intolerance","volume":"43","author":"Blanca-L\u00f3pez","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib88","first-page":"24","article-title":"Clinical management of adult patients with a history of nonsteroidalanti-inflammatory drug-induced urticaria\/angioedema: update","volume":"3","author":"Asero","year":"2007","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098611422558","article-title":"Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients","volume":"2","author":"Lambrakis","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jaip.2021.03.034_bib90","doi-asserted-by":"crossref","first-page":"e004368","DOI":"10.1161\/CIRCINTERVENTIONS.116.004368","article-title":"Aspirin desensitization in patients with coronary artery disease: results of the multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease)","volume":"10","author":"Rossini","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jaip.2021.03.034_bib91","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1398-9995.2011.02684.x","article-title":"Response to a selective COX-2 inhibitor in patients with urticaria\/angioedema induced by nonsteroidal anti-inflammatory drugs","volume":"66","author":"Do\u00f1a","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.034_bib92","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1345\/aph.1P630","article-title":"The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"45","author":"Beavers","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2021.03.034_bib93","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1751-7176.2011.00438.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics. A pooled analysis of clinical experience of 12,942 patients","volume":"13","author":"White","year":"2011","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.jaip.2021.03.034_bib94","doi-asserted-by":"crossref","first-page":"e0230632","DOI":"10.1371\/journal.pone.0230632","article-title":"Angioedemas associated with renin-angiotensin system blocking drugs: comparative analysis of spontaneous adverse drug reaction reports","volume":"15","author":"Dubrall","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.03.034_bib95","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/2013.jamainternmed.34","article-title":"Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system","volume":"172","author":"Toh","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","article-title":"Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study","volume":"264","author":"Shi","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaip.2021.03.034_bib97","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jaip.2021.03.034_bib98","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2010.02973.x","article-title":"Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report","volume":"27","author":"Skalli","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib99","first-page":"e1598","article-title":"Pathogenesis of drug induced nonallergic angioedema: a review of unusual etiologies","volume":"9","author":"Kalambay","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2021.03.034_bib100","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1111\/dme.12134","article-title":"Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?","volume":"30","author":"Saisho","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib101","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jnnp-2014-308097","article-title":"Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke","volume":"86","author":"Hurford","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaip.2021.03.034_bib102","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.yjmcc.2007.08.007","article-title":"Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells","volume":"43","author":"Liesmaa","year":"2007","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jaip.2021.03.034_bib103","first-page":"e2965","article-title":"Fransawy Alkomos M, Zarghamravanbakhsh P, Sachmechi I. Drug-induced angioedema: a rare side effect of rosuvastatin","volume":"10","author":"Shahbaz","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2021.03.034_bib104","first-page":"149","article-title":"Simvastatin: a risk factor for angioedema?","volume":"29","author":"Nisly","year":"2013","journal-title":"J\u00a0Pharm Technol"},{"key":"10.1016\/j.jaip.2021.03.034_bib105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01526-7","article-title":"Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy","volume":"114","author":"Bork","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2021.03.034_bib106","first-page":"388","article-title":"Repeated massive tongue swelling due to the combined use of estramustine phosphate and angiotensin-converting enzyme inhibitor","volume":"16","author":"Kamata","year":"2006","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.034_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12245-017-0141-z","article-title":"Angioedema in the emergency department: a practical guide to differential diagnosis and management","volume":"10","author":"Bernstein","year":"2017","journal-title":"Int J Emerg Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821003792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821003792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:27:06Z","timestamp":1761974826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821003792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2213219821003792"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.034","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}